Organization
Nuffield Orthopaedic Centre, Oxford, United Kingdom
2 abstracts
Abstract
ACHIEVEMENT OF PASDAS LOW DISEASE ACTIVITY AND VERY LOW DISEASE ACTIVITY IN PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH CERTOLIZUMAB PEGOL OVER 4 YEARS AND THE OVERLAP WITH DAPSA AND MDA DISEASE ACTIVITY TARGETSOrg: Nuffield Orthopaedic Centre, Oxford, United Kingdom, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, United States of america, St Vincent’s University Hospital and Conway institute for Biomolecular Research, University College Dublin, Dublin, Ireland, Division of Rheumatology allergy and Immunology, UC San Diego School of Medicine, La Jolla, CA, United States of america, Department of Dermatology, ICahn School of Medicine at Mt Sinai, New York, NY, United States of america,
Abstract
BIMEKIZUMAB-TREATED PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS SHOWED SUSTAINED ACHIEVEMENT OF MINIMAL DISEASE ACTIVITY AND REMISSION: UP TO 2-YEAR RESULTS FROM TWO PHASE 3 STUDIESOrg: Nuffield Orthopaedic Centre, Oxford, United Kingdom, Oxford University Hospitals NHS Trust, University of Oxford and Oxford Biomedical Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Diseases, Oxford, United Kingdom, Copenhagen University Hospital, The Parker Institute, Bispebjerg and Frederiksberg, Denmark, University of Pennsylvania, Perelman School of Medicine, Philadelphia, United States of America, Royal National Hospital of Rheumatic Diseases, Bath, United Kingdom,